Meloxadin Oral Suspension (Canada)

This treatment applies to the following species:

Dogs

Company: Vetoquinol

Meloxicam Suspension

Veterinary Use Only

DIN 02485621

Description

Each mL contains 1.5 mg meloxicam in a yellowish green suspension.

Meloxadin Oral Suspension Indications

Meloxadin Oral Suspension is a nonsteroidal anti- inflammatory drug (NSAID) of the oxicam group for use in dogs. It acts by inhibition of prostaglandin synthesis and is indicated for the alleviation of inflammation and pain in both acute and chronic musculo-skeletal disorders.

Dosage and Administration

Meloxadin Oral Suspension should be administered mixed with food. On the first day of treatment, a single dose of 0.2 mg meloxicam/kg body weight should be given. Treatment is to be continued once daily by oral administration (at 24 hour intervals) at a maintenance dose of 0.1 mg meloxicam/kg body weight.

Instructions for use: Particular care should be given with regard to the accuracy of dosing. The suspension can be given using either the Meloxadin 1 mL syringe (for very small breeds) - which provides graduation lines to indicate meloxicam dosage per 0.5 kg. - or the Meloxadin 5 mL measuring syringe - which provides graduation lines to indicate meloxicam dosage for every 2.5 kg. Both syringes are provided in the package (see below). The syringe fits on to the bottle and has a kg-body weight scale designed for the maintenance dose (i.e. 0.1 mg meloxicam/kg body weight). Thus twice the volume should be administered on the first day as the initial dose. Shake well before use. Please carefully follow the instructions of the veterinarian.

For dogs 15 kg or greater, the large dosing syringe provided in the package should be used (see dosing procedure below). The large dosing syringe fits onto the bottle and has dosing marks in 2.5 kg increments (up to 72.5 kg), designed to deliver the daily maintenance dose of 0.1 mg/kg. When using the large syringe, the dog’s weight should be rounded down to the nearest 2.5 kg increment. Replace and tighten cap after use.

Dosing procedure using the measuring syringe:

1. Pull the plunger back to the approximate volume required.

2. Adjust dosage volume to the corresponding body weight.

Twist the bottle and the syringe in opposite directions and pull apart.

Empty the contents of the syringe over the feed.

Improvement is normally seen within 3-4 days. Treatment should be discontinued after 10 days at the latest if no improvement is apparent.

Contraindications

Meloxadin Oral Suspension should not be administered if gastric or intestinal ulceration or bleeding is suspected: if there is evidence of cardiac, hepatic or renal disease; or if there is evidence of a hemorrhagic disorder or individual hypersensitivity to the product. Do not administer concurrently, other steroidal or nonsteroidal anti-inflammatory drugs (NSAIDs), aminoglycoside antibiotics or anticoagulant agents. Pretreatment with other steroidal or nonsteroidal anti-inflammatory drugs (NSAIDs) may result in additional or increased effects and accordingly a treatment-free period with such drugs should be observed for at least 24 hours before commencement of treatment depending on the pharmacokinetic properties of the products used previously.

Meloxadin Oral Suspension Caution

Not approved for use in cats. Meloxadin Oral Suspension should not be administered to breeding, pregnant or lactating dogs. Do not exceed the stated dose. In case of overdosing, symptomatic treatment should be initiated.

Animals being treated with meloxicam should be monitored for the occurrence of side effects as susceptibility varies with the individual.

Adverse reactions reported with the NSAID class of drugs include gastrointestinal signs, renal and hepatic toxicity as well as hematological, neurological and dermatological abnormalities.

If gastrointestinal or other side effects occur, treatment should be discontinued.

As for all NSAIDs, use in any animal less than 6 weeks of age or in debilitated aged animals may involve additional risk. If use in such animals cannot be avoided, a reduced dosage and careful clinical management may be required.

Warning: Keep out of reach of children.

Adverse Effects: The safety profile of meloxicam has been evaluated in well controlled target animal safety studies in the dog. Dogs treated with placebo, 1X, 3X and 5X label dosages were closely monitored over a 180 day (26 weeks) period. The study determined that there were no drug related adverse effects on clinical observations, normal body weight gain, food consumption, physical and ophthalmic examinations, clotting times, mucosal bleeding times or on a panel of clinical pathology parameters monitored throughout the study. Postmarketing reports of suspected adverse drug reactions (SADRs) following field use of meloxicam have been monitored worldwide since 1995. Based on case reports received under a voluntary reporting system by veterinarians or pet owners/caregivers, the most important affected body system was the gastrointestinal tract followed in decreasing order by central nervous system/behavioral signs, renal and dermatological system. Case reports often did not provide sufficient information to establish cause of the signs observed. In most cases, adverse effects were transient and disappeared after termination of treatment. In rare cases however, death has been associated with some of these adverse reactions. The following suspected adverse effects have been reported:

Gastrointestinal: Vomiting, diarrhea, inappetence, melena, hematemesis, ulceration.

Central Nervous System/Behavioral: Ataxia, personality change, seizures, sleepiness, hyper-activity, depression, trembling.

Renal: Elevated creatinine and BUN, acute renal failure.

Dermatologic: Pruritus, eczema, focal alopecia, moist dermatitis (hot spots).

Hypersensitivity: Urticaria, allergic dermatitis.

Hematologic: Immune mediated hemolytic anemia, immune mediated thrombocytopenia.

Hepatic: Elevated liver enzymes, jaundice.

Information for Pet Owners: Meloxicam is a nonsteroidal anti-inflammatory drug (NSAID) and as with others in this group, side effects may occur in treated dogs. The most common adverse effects reported involve the gastro-intestinal tract and usually occur within the first week of treatment. Typical symptoms include loss of appetite, vomiting, diarrhea, dark stools and depression. It is important in these situations to discontinue treatment and contact your veterinarian. In most cases, the side effects are transient and disappear after termination of treatment but in rare instances may be serious. Dogs undergoing prolonged treatment with meloxicam should be monitored periodically. Consult your veterinarian.

Shake well before using.

Storage

Store at or below 25°C.

Presentation: Available in pack sizes of 10 mL, 32 mL, 100 mL, 2 x 100 mL plastic bottles. A Meloxadin measuring syringe is also provided in the pack.

Distributed by: Vetoquinol N.-A. Inc., 2000, ch. Georges, Lavaltrie, QC, Canada J5T 3S5

Manufactured by: Norbrook Laboratories Limited, Newry, BT35 6PU, Co. Down, Northern Ireland (UK)

Meloxadin™ is a trademark of Vetoquinol N.-A. Inc.

Revised April 2019

Net	Code
10 mL	457722	000491I02
32 mL	457723	005491I02
100 mL	457724	005491I02
2x100 mL	457725	005491I02

CPN: 1234461.0

VETOQUINOL N.-A. INC.
Commercial Division
2000, CHEMIN GEORGES, LAVALTRIE, QC, J5T 3S5

Telephone:		450-586-2252
Order Desk:		800-363-1700
Fax:		450-586-4649
Website:		www.vetoquinol.ca
Email:		info@vetoquinol.ca

THIS SERVICE AND DATA ARE PROVIDED "AS IS". Animalytix assumes no liability, and each user assumes full risk, responsibility, and liability, related to its use of the Animalytix service and data. See the Terms of Use for further details.